COMPASS Pathways (NASDAQ:CMPS) Price Target Lowered to $45.00 at HC Wainwright

COMPASS Pathways (NASDAQ:CMPS) had its price objective decreased by analysts at HC Wainwright from $60.00 to $45.00 in a report released on Thursday,Benzinga reports. The firm currently has a “buy” rating on the stock.

Other equities analysts also recently issued reports about the stock. Royal Bank of Canada reissued an “outperform” rating and set a $18.00 price target on shares of COMPASS Pathways in a report on Wednesday, January 15th. Maxim Group dropped their price objective on shares of COMPASS Pathways from $22.00 to $12.00 and set a “buy” rating for the company in a report on Friday, November 1st. Six investment analysts have rated the stock with a buy rating, According to MarketBeat.com, COMPASS Pathways currently has an average rating of “Buy” and a consensus price target of $30.60.

COMPASS Pathways Stock Up 3.4 %

Shares of NASDAQ CMPS opened at $4.25 on Thursday. COMPASS Pathways has a 52-week low of $3.16 and a 52-week high of $12.75. The company has a debt-to-equity ratio of 0.15, a quick ratio of 8.91 and a current ratio of 8.91. The business has a fifty day moving average of $4.09 and a two-hundred day moving average of $5.49. The stock has a market cap of $290.79 million, a PE ratio of -1.93 and a beta of 2.28.

Institutional Investors Weigh In On COMPASS Pathways

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Conservest Capital Advisors Inc. lifted its position in shares of COMPASS Pathways by 28.9% during the fourth quarter. Conservest Capital Advisors Inc. now owns 13,363 shares of the company’s stock worth $51,000 after purchasing an additional 3,000 shares in the last quarter. China Universal Asset Management Co. Ltd. acquired a new position in COMPASS Pathways during the 4th quarter worth $41,000. Wealthfront Advisers LLC acquired a new position in COMPASS Pathways during the 4th quarter worth $43,000. Flagship Harbor Advisors LLC bought a new position in COMPASS Pathways in the 4th quarter valued at $43,000. Finally, Franklin Resources Inc. increased its stake in shares of COMPASS Pathways by 4.4% in the 3rd quarter. Franklin Resources Inc. now owns 295,785 shares of the company’s stock valued at $1,810,000 after buying an additional 12,599 shares during the period. Institutional investors and hedge funds own 46.19% of the company’s stock.

COMPASS Pathways Company Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.